You are here: Home: Audio Program Guide: CCU 1 | 2006 Audio
 
  Go to interview with Herbert Hurwitz, MD
Go to interview with Peter C Enzinger, MD
Go to interview with Al B Benson III, MD
  To listen to individual tracks, click the on the headphone.
To download tracks, right-click on the one you wish to download.
Herbert Hurwitz, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Clinical Director, Phase I Program
Co-leader, GI Oncology Program
Duke University Medical Center
Durham, North Carolina
  
  Click here to download the entire interview  
Track 1 Introduction by Neil Love, MD
Track 2 Bevacizumab-associated hypertension
Track 3 Clinical evaluation of risk for bevacizumab-associated arteriovascular events
Track 4 Potential cardiovascular effects of bevacizumab
Track 5 Potential factors contributing to bowel perforations in studies of bevacizumab
Track 6 Bevacizumab-associated bleeding complications
Track 7 Management of bowel-related complications
Track 8 Timing of bevacizumab administration and surgery
Track 9 Effect of bevacizumab on hepatic regeneration
Track 10 Role of VEGF inhibition in the adjuvant setting
Track 11 Potential mechanisms of action of bevacizumab
Track 12 Clinical use of adjuvant bevacizumab
Track 13 Administration of bevacizumab beyond chemotherapy in the adjuvant setting
Track 14 Clinical activity of single-agent bevacizumab
Track 15 Continuation of bevacizumab after disease progression
Track 16 Determining the optimal dose of bevacizumab
Track 17 Evaluation of cetuximab and bevacizumab in combination
Track 18 Management of bevacizumab-related side effects
Track 19 Pharmacoeconomic evaluation of novel therapies
Track 20 Combining capecitabine with bevacizumab
     
Peter C Enzinger, MD
Instructor in Medicine, Harvard Medical School
Clinical Director, Gastrointestinal Cancer Center
Dana-Farber Cancer Institute
Boston, Massachusetts
  
  Click here to download the entire interview  
Track 1 Introduction by Neil Love, MD
Track 2 Comparison of NSABP-C-07 and MOSAIC adjuvant trial outcomes
Track 3 Preservation of oxaliplatin dose intensity during adjuvant therapy
Track 4 Use of calcium and magnesium for oxaliplatin-associated neuropathy
Track 5 Dose attenuation or discontinuation for oxaliplatin-associated neuropathy
Track 6 Probability of residual neuropathy after oxaliplatin-containing chemotherapy
Track 7 X-ACT adjuvant trial: Capecitabine versus Mayo Clinic 5-FU regimen
Track 8 Selecting appropriate patients to receive capecitabine as adjuvant therapy
Track 9 Dosing capecitabine in the adjuvant and metastatic settings
Track 10 Differences in North American and European tolerance to capecitabine dosing
Track 11 Evaluating patients for selection of initial therapy in the metastatic setting
Track 12 Bevacizumab-associated toxicities
Track 13 Potential mechanisms of action of bevacizumab
Track 14 Selection of second-line therapy after progression on a bevacizumab-containing regimen
Track 15 Side effects and tolerability of bevacizumab and cetuximab
Track 16 Rationale for evaluating bevacizumab in adjuvant clinical trials
Track 17 CALGB-C80405: Cetuximab and/or bevacizumab and FOLFOX or FOLFIRI in the metastatic setting
Track 18 Therapeutic approach to patients with Stage II disease
Track 19 Clinical trials evaluating the benefit of adjuvant chemotherapy in Stage II disease
Track 20 Laparoscopic colectomy and number of nodes removed
     
Al B Benson III, MD
Professor of Medicine
Associate Director for Clinical Investigations
Robert H Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois
  
  Click here to download the entire interview  
Track 1 Introduction by Neil Love, MD
Track 2 Allelic loss of chromosome 18q and prognosis in colorectal cancer
Track 3 ECOG-E5202: FOLFOX with or without bevacizumab in molecularly identified high-risk Stage II disease
Track 4 ECOG-E5202: Eligibility criteria
Track 5 ECOG-E5202: Duration of bevacizumab therapy
Track 6 ASCO treatment guidelines for Stage II disease
Track 7 Current and potential future strategies to select patients for adjuvant therapy
Track 8 Alternative methods of 5-FU administration